Business Wire

Sixth Street Welcomes Julian Salisbury as Partner and Co-Chief Investment Officer

Share

Sixth Street, a leading global investment firm, today announced that Julian Salisbury will become a partner of the firm and serve as Co-Chief Investment Officer alongside Chief Executive Officer Alan Waxman and Co-President Joshua Easterly. Salisbury is expected to start in early 2024 and will help lead Sixth Street alongside Waxman, Easterly, Vice Chairman R. Martin Chavez, Co-President David Stiepleman and the firm’s Executive Committee.

Salisbury brings to Sixth Street over 25 years of experience building and leading private and public markets investing businesses. He comes to the firm after a distinguished career at Goldman Sachs, where he most recently served as Chief Investment Officer of the Asset and Wealth Management Division. In that role, he was responsible for $2.7 trillion in assets, including more than $450 billion in alternative investments. Salisbury was previously Co-Head of Goldman Sachs Asset Management and Global Head of the Merchant Banking Division.

Prior to forming Sixth Street in 2009, many of the firm’s co-founding partners worked closely with Salisbury at Goldman Sachs while building and leading investing businesses focused on growth investing, alternative energy, real estate, direct lending, and public markets strategies, among others.

“Sixth Street’s culture is the foundation of everything we do, and Julian is a seamless fit into our firm. He has distinguished himself time and again as a superstar investor and business builder and, more importantly, as a trustworthy and reliable partner,” said Sixth Street Chief Executive Officer Alan Waxman. “Julian understands how asset owners’ needs and objectives drive the flow of capital around the world, and he embodies our firm’s values of teamwork, integrity, entrepreneurship, and making a positive impact on our communities. We first got to know each other in 2002 while working on an investment in a Swiss cable company, and since then my partners and I have cheered Julian on as he has become one of the industry’s best investors and business leaders. We are incredibly excited to be back working with him again.”

Salisbury’s career is defined by an extraordinary range of investing, business-building, and leadership experience throughout the Americas, Europe, and Asia. In addition to his role as CIO of Asset and Wealth Management, he co-chaired investment committees at Goldman Sachs across all direct private strategies including growth, real estate, private credit, private equity, and infrastructure. He was named to the Goldman Sachs Management Committee in 2017 and previously co-chaired the firm’s Partnership Committee. Salisbury serves numerous charitable and community-focused organizations, including as a director on the boards of Sponsors for Educational Opportunity (SEO) and Save the Children.

“Alan and the team at Sixth Street have assembled the exact kind of organization I would want if I were creating an investment firm from the ground up. Sixth Street’s culture, platform architecture, and investment philosophy fully align with what I consider the model for how to build and operate a modern investment firm,” said incoming Sixth Street Partner and Co-Chief Investment Officer Julian Salisbury. “While leaving Goldman Sachs was a difficult decision, this was a unique opportunity to reunite with a group of people for whom I have deep, longstanding respect. Alan and I have been colleagues and friends for more than twenty years, and I am incredibly excited to work with him, Josh, David, and Marty again as a member of the powerful investing ecosystem the Sixth Street partner group has cultivated. There really is no other firm I would have considered joining, and I am excited for all that I know we will achieve together.”

As a global investment firm designed for cross-platform collaboration at scale, Sixth Street pursues a highly flexible investment mandate: the firm invests for growth, builds new partnerships, acquires assets, provides direct financing, and regularly creates first-of-their-kind capital solutions for companies and assets customized to meet the strategic objectives of management teams. Sixth Street’s more than 500 investment and control-side professionals operate as one unified team working on behalf of the firm’s institutional investors and their beneficiaries around the world. The firm’s investments and strategic partnerships across sectors and geographies have included Airbnb, AirTrunk, Bay FC, Biohaven, FC Barcelona, Legends, Real Madrid, San Antonio Spurs, and Spotify, among many others.

About Sixth Street

Sixth Street is a leading global investment firm with over $65 billion in assets under management and committed capital. The firm’s Sixth Street TAO platform also includes Talcott Financial Group, an international life insurance group with $123 billion in assets under management. Sixth Street uses its long-term flexible capital, data-enabled capabilities, and One Team culture to develop themes and offer solutions to companies across all stages of growth. For more information, follow Sixth Street on social media and visit www.sixthstreet.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Sixth Street
Patrick Clifford
pclifford@sixthstreet.com
+1-646-906-4339

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye